Living Medicines and Microbial Therapeutics Market is expected to reach USD 2.5 billion by 2031

Living Medicines and Microbial Therapeutics Market Trends & Forecast

According to a research study published by Knowledge Sourcing Intelligence (KSI), the living medicines and microbial therapeutics market will expand from USD 1.4 billion in 2026 to USD 2.5 billion in 2031 at a CAGR of 12.3% during the forecast period.

The living medicines and microbial therapeutics market is becoming one of the most revolutionary sectors in biotechnology and precision medicine. It is gaining ground due to an increasing scientific understanding of the human microbiome and how it affects immunity, metabolism, gastrointestinal health, and the development of chronic diseases. Living medicines, which are fundamentally different from traditional drugs, rely on engineered or naturally occurring microbes to carry out specific biological functions in the human body for the purpose of disease prevention, diagnosis, or treatment. Pharmaceutical and biotech companies are progressively turning to microbiome-based therapeutic strategies for ailments like inflammatory bowel disease, recurrent Clostridioides difficile infection, cancer, metabolic disorders, and brain diseases.

Request a free sample copy or view the report summary: Living Medicines and Microbial Therapeutics Market Report

Living Medicines and Microbial Therapeutics Market Report Highlights

• The Engineered Microbial Therapeutics segment in the living medicines and microbial therapeutics market is projected to experience the highest growth rate. This is largely because of the quick progress being made in synthetic biology, genetic engineering, and precision medicine. Such therapies are intended to carry out specific therapeutic functions within the body and as a result, they allow more personalized and disease-specific treatment options. Moreover, various factors such as the rising number of clinical research studies, the increasing flow of capital from biotech firms, and the widening use of these treatments in cancer, digestive and metabolic diseases are majorly contributing to the growth of this segment.

• The segment of Neurological & Psychiatric Conditions is expected to show the fastest growth due to the increasing number of studies related to the gut-brain axis and the contribution of the microbiome to mental and neurological health. Both, scholars and drug manufacturers are furthering their studies on the use of microorganisms for therapeutic purposes for diseases like depression, anxiety, and autism spectrum disorders, as well as neurodegenerative disorders. Increasing knowledge of the microbiome's impact on the brain and a rising desire for new and effective treatments for mental health issues are speeding up the growth of this area.

• Research & Diagnostic Laboratories is expected to be the fastest-growing end-user segment because of the expansion of microbiome research, increase in clinical trials, and higher demand for state-of-the-art microbial analysis and diagnostic technologies.

• North America is anticipated to be the regional leader in the living medicines and microbial therapeutics market growth. This will be supported further by the region's solid biotechnology infrastructure, the increase in microbiome research investments, and the presence of a concentration of big pharmaceutical and biotech companies. The region is also experiencing a high number of clinical trials along with increasing regulatory approvals for microbiome-based therapies, especially in the US. Besides, factors such as the rise in gastrointestinal and metabolic diseases and the increasing use of precision medicine are majorly fueling market growth in this region.

Living Medicines and Microbial Therapeutics Market Growth Drivers and Restraints

Growth Drivers:

• Rising Focus on Microbiome-Based Therapeutics: The rapidly increasing knowledge of the human microbiome and its role in immunity, metabolism, gastrointestinal health, and neurological function has become a major factor driving demand for live biologics and microbial therapeutics. Moreover, research continues to reveal the association between microbial imbalance and chronic diseases, which in turn stimulates efforts in the development of microbiome-targeted therapies.

• Increasing Prevalence of Chronic and Gastrointestinal Diseases: New cases of inflammatory bowel disease, irritable bowel syndrome, obesity, diabetes, autoimmune disorders, and repeated bacterial infections have been increasing, which leads to the strong need for new therapies. Living medicines provide targeted and possibly long-term therapeutic benefits; hence, they are alternative options to conventional drug treatments.

Restraints:

• Complex Regulatory Frameworks: Despite ongoing progress, regulatory pathways for living medicines and microbial therapeutics remain complex and evolving. Differences in manufacturing standards, safety requirements, and clinical validation guidelines across regions can delay product approvals and commercialization timelines.

Living Medicines and Microbial Therapeutics Market Key Development

• Research and Development: In November 2025, Siolta Therapeutics disclosed favorable results from their Phase 2 study of STMC-103H, an oral microbial treatment, for the prevention of allergic diseases. They are preparing for more clinical presentations in 2026, which marks an important milestone towards their possible commercial launches in the future.

• Research and Development: In February 2025, Assembly Biosciences, Inc. unveiled the positive Phase 1a results for ABI-1179. These data demonstrate Assembly Biosciences' expertise in developing novel microbiome-derived therapeutics and confirm the company's strategic positioning in the live biotherapeutics market.

Living Medicines and Microbial Therapeutics Market Segmentation

Knowledge Sourcing Intelligence has segmented the living medicines and microbial therapeutics market based on therapeutic application, product type, end-user, and region:

Living Medicines and Microbial Therapeutics Market, By Product Type

• Live Biotherapeutic Products (LBPs)

• Probiotics

• Prebiotics

• Synbiotics

• Postbiotics

• Microbial Consortia

• Engineered Microbial Therapeutics

Living Medicines and Microbial Therapeutics Market, By Therapeutic Application

• Gastrointestinal Disorders

• Metabolic Diseases

• Infectious Diseases

• Autoimmune and Inflammatory Disorders

• Oncology Supportive Therapies

• Neurological & Psychiatric Conditions

• Rare Genetic Disorders

• Others

Living Medicines and Microbial Therapeutics Market, By End User

• Hospitals & Clinics

• Specialty Clinics

• Research & Diagnostic Laboratories

• Home Healthcare

• Others

Living Medicines and Microbial Therapeutics Market, By Region

• North America

  • USA

  • Canada

  • Mexico

• Europe

  • United Kingdom

  • Germany

  • France

  • Spain

  • Others

• Asia Pacific

  • China

  • India

  • Japan

  • South Korea

  • Indonesia

  • Thailand

  • Others

• South America

  • Brazil

  • Argentina

  • Others

• Middle East and Africa (MEA)

  • Saudi Arabia

  • UAE

  • Others

Living Medicines and Microbial Therapeutics Market Key Players

• Seres Therapeutics

• Vedanta Biosciences

• Rebiotix Inc.

• Finch Therapeutics

• 4D Pharma plc

• Synlogic

• Enterome

• Evelo Biosciences

• Microbiotica

• Second Genome